Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of metabolic syndrome,
is one of the most common chronic liver diseases, which may progress to fibrosis, cirrhosis …

Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of approximately 25%
and is associated with high morbidity and high mortality. NAFLD is a leading cause of …

Non‐alcoholic fatty liver disease (NAFLD) has been known as the hepatic feature of
metabolic syndrome. Extra fat depots, especially in visceral areas, develop insulin …

The contemporary pathophysiological model of non-alcoholic fatty liver disease (NAFLD)
comprises multiple parallel pathways with a dynamic cross talk that cumulate in steatosis …

Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat in the liver despite a low
level of alcohol intake, with signs of hepatomegaly. Although in the past, NAFLD was …

The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing rapidly worldwide;
however, there are currently limited treatments for NAFLD. The disease spectrum includes …

Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic accretion
of triacylglycerides in the absence of alcohol intake that may progress to steatohepatitis …

Abstract Non‐alcoholic steatohepatitis (NASH), the progressive form of non‐alcoholic fatty
liver disease (NAFLD), is emerging as a main health problem in industrialized countries …

Non-alcoholic fatty liver disease (NAFLD) is a major cause of liver diseases, and is closely
related to metabolic syndrome and its related conditions, diabetes mellitus and dyslipidemia …

Non‐alcoholic fatty liver disease (NAFLD) may vary from moderately mild non‐alcohol fatty
liver (NAFL) towards the malignant variant known as non‐alcoholic steatohepatitis (NASH) …